Cargando…

Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy

Tumor lysis syndrome (TLS) is a potentially life-threatening complication of cancer therapy characterized by two or more of the following laboratory abnormalities: hyperuricemia, hyperkalemia, hypocalcemia, and hyperphosphatemia, with resultant end-organ damage, eg, renal failure, seizures, or cardi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dinnel, Jennifer, Moore, Bonny L, Skiver, Brent M, Bose, Prithviraj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298251/ https://www.ncbi.nlm.nih.gov/pubmed/25610345 http://dx.doi.org/10.2147/CE.S54995

Ejemplares similares

Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase
por: Alakel, Nael, et al.
Publicado: (2017)

Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout
por: Cammalleri, Lisa, et al.
Publicado: (2007)

Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series
por: Latha, S. M., et al.
Publicado: (2015)

A Case Report of Newly Diagnosed Epithelial Ovarian Carcinoma Presenting with Spontaneous Tumor Lysis Syndrome and Its Successful Management with Rasburicase
por: Shukla, Deepak Kumar, et al.
Publicado: (2017)

Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase)
por: Pession, Andrea, et al.
Publicado: (2008)

Rasburicase-Induced Falsely Low Measurement of Uric Acid in Tumor Lysis Syndrome: A Report of Two Cases
por: Yu, Lian, et al.
Publicado: (2023)

Rasburicase-Induced Methemoglobinemia
por: Ahmed, Moeed, et al.
Publicado: (2021)

Transient myeloproliferative disorder in a newborn with down syndrome treated with rasburicase for the risk of development of tumor lysis syndrome: A case report
por: Tragiannidis, Athanasios, et al.
Publicado: (2011)

Not the Typical Pneumonia: An Unusual Case of Rasburicase-induced Methomoglobinemia
por: Younis, Moustafa, et al.
Publicado: (2018)

One for the road! A study to assess the efficacy of single low-dose regimen of rasburicase in controlling hyperuricaemia in patients with tumour lysis syndrome due to haematological malignancies
por: Azim, Hamdy A, et al.
Publicado: (2013)

Emerging role of rasburicase in the management of increased plasma uric acid levels in patients with hematologic malignancies
por: Kennedy, LeAnne D, et al.
Publicado: (2011)

Rasburicase‐induced methemoglobinemia: case report, literature review, and proposed treatment algorithm
por: Sherwood, Garrett B., et al.
Publicado: (2016)

Rasburicase-Induced Methemoglobinemia in a Patient with Aggressive Non-Hodgkin’s Lymphoma
por: Alessa, Mohammed A., et al.
Publicado: (2015)

Managing Tumor Lysis Syndrome in the Era of Novel Cancer Therapies
por: McBride, Ali, et al.
Publicado: (2017)

Diagnosis and management of tumor lysis syndrome.
por: Puri, Isha, et al.
Publicado: (2020)

Dissolution of extensive urolithiasis: extending the utility of rasburicase can avoid the need for surgical intervention and renal replacement therapy
por: Rezvani, Sean, et al.
Publicado: (2016)

Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies
por: Pei, Yuxin, et al.
Publicado: (2020)

Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy
por: Angeloni, Emiliano
Publicado: (2016)

Micafungin: an evidence-based review of its place in therapy
por: de la Torre, Pola, et al.
Publicado: (2014)

A Case of Type 2 Hypersensitivity to Rasburicase Diagnosed with a Natural Killer Cell Activation Assay
por: Viel, Sébastien, et al.
Publicado: (2018)

Rasburicase induced severe hemolysis and methemoglobinemia in a Caucasian patient complicated by acute renal failure and ARDS
por: Raru, Yonas, et al.
Publicado: (2018)

Prevention and Management of Tumor Lysis Syndrome in Adults With Malignancy
por: Sarno, Jessica
Publicado: (2013)

Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy
por: Buti, Sebastiano, et al.
Publicado: (2016)

Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy
por: Serratrice, Christine, et al.
Publicado: (2016)

Infliximab: the evidence for its place in therapy in ulcerative colitis
por: Van Assche, Gert, et al.
Publicado: (2007)

Survey of Anaphylaxis during Rasburicase Re-Administration in Patients with Hematological Malignancies Using a Japanese Claims Database
por: Kobayashi, Shunsuke, et al.
Publicado: (2022)

MF management
por: Bose, Prithviraj, et al.
Publicado: (2019)

Spontaneous Tumor Lysis Syndrome
por: Wesemüller, Wiebke, et al.
Publicado: (2020)

Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy
por: Hennigan, Stephanie, et al.
Publicado: (2007)

Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy
por: Tonin, Fernanda S, et al.
Publicado: (2016)

Benefit of continuous kidney replacement therapy for managing tumor lysis syndrome in children with hematologic malignancies
por: Anderson, Ashlea, et al.
Publicado: (2023)

Metastatic testicular cancer presenting with liver and kidney dysfunction treated with modified BEP chemotherapy combined with continuous hemodiafiltration and rasburicase
por: Kimakura, Mai, et al.
Publicado: (2016)

Updates in the management of polycythemia vera and essential thrombocythemia
por: Bose, Prithviraj, et al.
Publicado: (2019)

Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy
por: Lieberman, Daniel Z, et al.
Publicado: (2010)

Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy
por: Graff, Julie N, et al.
Publicado: (2014)

Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy
por: Jang, Ji Hye, et al.
Publicado: (2015)

Belatacept for the prophylaxis of organ rejection in kidney transplant patients: an evidence-based review of its place in therapy
por: Hardinger, Karen L, et al.
Publicado: (2016)

Tumor lysis syndrome developing intraoperatively
por: Verma, Ankur, et al.
Publicado: (2011)

Tumor lysis syndrome in childhood malignancies
por: Cheung, Wing Lum, et al.
Publicado: (2020)

Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies
por: Robinson, Katherine M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jqjiteedku12ub9913en9gdih7